#United States #New York #Securities Fraud #Pomerantz #Nyxoah

Pomerantz Law Firm Investigates Claims Against Nyxoah S.A.

On April 22, 2025, Pomerantz LLP announced an investigation involving investors of Nyxoah S.A. This inquiry targets whether the company, alongside certain officers and directors, has engaged in securities fraud or other illicit business practices. The firm's scrutiny arises in light of recent developments that may significantly affect the company's stock and investor interests.

Previously, on March 25, 2025, Nyxoah openly communicated significant news regarding the FDA's stance on its Genio® system. An Approvable Letter was issued, indicating that the U.S. Food and Drug Administration had found the company's Pre-Market Approval (PMA) application largely met required standards. This result suggests that Nyxoah's device could eventually be marketed in the U.S. Following the FDA's communication, the approval hinged on a satisfactory review of the company's manufacturing controls and methods. This process introduces uncertainty pertaining to the timing of Genio's commercial launch, causing analysts to project potential delays.

Following this announcement, the repercussions were immediate. Nyxoah's stock price plummeted by $2.42 per share, reflecting a dramatic 21.36% drop, closing at $8.91 per share the day after the announcement. Such a decline raises considerable concern among investors and stakeholders, drawing the attention of Pomerantz LLP, which has a longstanding reputation in handling corporate, securities, and antitrust class litigation.

Pomerantz LLP, recognized as one of the leading law firms in the sector, continues the legacy started by its founder, the late Abraham L. Pomerantz. With over 85 years of experience, the firm is committed to advocating for victims of securities fraud and corporate misconduct. Their history includes recovering substantial damages for class members affected by fraudulent activities.

For investors considering action, Pomerantz urges them to reach out to Danielle Peyton at [email protected] or via telephone at 646-581-9980, ext. 7980. Being part of the investigation could allow affected parties to voice concerns about potential mismanagement and fraudulent actions, while seeking justice in the wake of Nyxoah's recent challenges.

As the legal landscape around corporate governance evolves, ongoing investigations like the one initiated by Pomerantz will undoubtedly influence the future operations and reputation of Nyxoah S.A. The confluence of FDA approvals intertwined with the allegations of impropriety creates a pivotal moment for investors seeking clarity and accountability within the company. Investor confidence, contingent on legal and business integrity, remains a cornerstone for Nyxoah's recovery and potential market success.